奥曲肽输注1天与5天治疗急性食管静脉曲张出血的随机对照试验
这项在泰国开展的全国多中心、非劣效性、开放标签随机对照试验纳入220例肝硬化急性食管静脉曲张出血并成功行内镜下套扎的患者,比较1天(n=109)与5天(n=111)持续奥曲肽输注方案。结果显示两组5天再出血率、6周再出血率和6周全因死亡率相似,1天组输血需求更少、恢复经口进食和住院时间更短,提示1天方案在预防5天再出血方面非劣效于5天方案。
要点
- 内镜套扎成功后,1天奥曲肽方案预防5天再出血非劣效于5天方案。
- 两组6周再出血率和6周全因死亡率无显著差异。
- 1天组输血更少、经口进食更早、住院时间更短。
核心结论
- 内镜套扎成功后,1天奥曲肽输注在预防5天再出血方面非劣效于标准5天方案。
- 1天与5天方案在6周再出血和6周全因死亡率方面无显著差异。
- 1天方案可减少输血需求并缩短至经口进食时间和住院时间。
研究设计与样本
- 全国多中心、非劣效性、开放标签、随机对照试验,在泰国5家三级医院和3家大学附属医院开展,共纳入220例肝硬化急性食管静脉曲张出血并接受内镜下套扎的患者。
- 患者随机接受1天(n=109)或5天(n=111)持续奥曲肽输注,主要结局为5天再出血(非劣效性框架),次要结局包括6周再出血和全因死亡率。
主要发现
- 5天再出血率1天组1.83% vs 5天组1.80%(P ≥ 0.99)。
- 6周再出血率1天组8.26% vs 5天组10.81%(P = 0.52)。
- 6周全因死亡率1天组5.50% vs 5天组6.31%(P = 0.80)。
- 早期再出血事件率差为0.03%,提示非劣效(95% CI,3.50%-3.56%)。
- 1天组输血需求显著更少,至经口进食时间和住院时间更短。
关键数值与推荐
- 主要终点5天再出血的非劣效性通过事件率差0.03%(95% CI,3.50%-3.56%)判定。
- 6周再出血和6周全因死亡率在1天与5天组间差异无统计学意义(P = 0.52和P = 0.80)。
临床怎么用
- 对于肝硬化急性食管静脉曲张出血且内镜套扎成功的患者,可考虑采用1天奥曲肽输注方案替代5天标准方案。
- 1天方案可能减少输血需求、加快恢复经口进食并缩短住院时间。
局限性
- 开放标签设计可能引入偏倚。
- 研究在泰国开展,结果外推需考虑人群和医疗环境差异。
- 样本量220例,事件数较少,需更大样本验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: The optimal duration of octreotide infusion for esophageal variceal bleeding remains unclear. We aimed to compare the efficacy of 1-day vs 5-day octreotide infusion combined with endoscopic therapy, with the primary outcome of early (5-day) rebleeding under a noninferiority framework and secondary outcomes of 6-week rebleeding and all-cause mortality. METHODS: This nationwide, multicenter, noninferiority, open-label, randomized, controlled trial included 220 patients with cirrhosis and acute esophageal variceal bleeding who underwent endoscopic band ligation in 5 tertiary-care and 3 university-based hospitals across Thailand. They received a 1-day (n = 109) or 5-day (n = 111) regimen of continuous octreotide infusion after successful endoscopy. Rebleeding, transfusion requirements, and mortality were assessed. RESULTS: Most participants were men (180/220), and the average age was 56 years. The 5-day rebleeding (1.83% vs 1.80%, P ≥ 0.99), 6-week rebleeding (8.26% vs 10.81%, P = 0.52), and 6-week all-cause mortality (5.50% vs 6.31%, P = 0.80) rates were similar between the 1-day and 5-day groups. The event-rate difference in early rebleeding was 0.03%, indicating noninferiority (95% CI, 3.50%-3.56%). Patients in the 1-day group required significantly fewer blood transfusions and had a shorter time to oral diet and shorter hospital stay. DISCUSSION: After successful endoscopic band ligation, the 1-day regimen of octreotide had a noninferior effect compared with the standard 5-day regimen in the prevention of 5-day rebleeding and exhibited no significant differences in the prevention of 6-week rebleeding and all-cause mortality. Trial registration number: Thai Clinical Trials Registry, TCTR 20221004008.
引用
- Chirapongsathorn S, Chang A, Malikhao S, et al. One vs Five Days of Octreotide Infusion for Acute Esophageal Variceal Bleeding: A Randomized Controlled Trial. Am J Gastroenterol. 2025. PMID: 41090987. doi:10.14309/ajg.0000000000003791
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。